MILANO ( – KOLINPHARMA is in second place in the special ranking of ‘Growth Leaders’ created by Il Sole 24 Ore for Italian companies, together with Statista. The ranking is related to the 350 Italian companies that have achieved the highest revenue growth in the period between 2014-2017. The criteria taken into consideration were: growth predominantly organic, a starting turnover of at least 100,000 euros, a registered office in Italy, being an independent entity (not part of a group). The selection started with a sample of 6,000 companies with the potential requirements, and these were invited to take part in the competition. “We are particularly proud of this recognition – commented Emanuele Lusenti, CEO of KOLINPHARMA and Rita Paola Petrelli, Chairman -, which confirms the value of our careful managerial and strategic choices and our vision of the market, carried out since the beginning. We have gone from 147,000 euros in 2016 to over 4 million in turnover in 2017 with an increase in revenues of over 202%, which puts us in second place in this prestigious ranking. The growth, the innovation, but above all the preclinical and clinical demonstration of the effectiveness of our products, almost all patented, will remain, in the coming years, our primary objectives, focusing on scientific dissemination towards a specialised medical class.”